Wefight has created an AI-powered Virtual Companion called Vik to support every patient with cancer and chronic diseases. To that end, Vik empowers and engages patients by answering their questions 24/7 and providing them with the right information at the right time throughout their healthcare journey. At the same time, Vik collects real-world data and …

hema.to provides fully automated, AI-powered diagnosis recommendations for blood cancer from flow cytometry data. This, in turn, increases efficiency and quality for hemato-oncology labs using hema.to’s cloud-based platform. In order to use it, diagnosticians upload flow data files, and the solution provides them with clinical indications and diagnostic recommendations, which follow expert consensus.

Tagworks Pharmaceuticals is a precision therapy company and a pioneer of the Click-to-Release approach. Leveraging its patent-protected technology platform, it aims to create a new standard of care for patients suffering from severe diseases, including cancer. With operations in the Netherlands and the U.S., Tagworks is developing a pipeline of click-cleavable therapies. Its lead program, …

Formerly called Tribvn Healthcare, Tribun Health powers the digital transformation of cancer diagnosis by designing innovative solutions. These solutions enable the management, analysis, and sharing of cellular images for both diagnostic laboratories and pharmaceutical/biotech companies. They use AI to support physicians and researchers in their diagnostic decision-making and scientific evaluation for the sake of patients. …

Dark Blue Therapeutics is an innovative drug discovery biotechnology company leveraging ground-breaking cancer biology insights from Oxford University to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology, Dark Blue Therapeutics matches its precision medicines to molecularly defined patient populations to develop transformative, durable …

Proxygen develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. It is focused on particular small molecules called “molecular glue degraders,” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome for degradation. Hence, instead of …

Orakl leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With its platform, the company partners with oncology players to identify relevant targets and deliver new drugs, faster.

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of “Marie Curie” whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”) …

T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully human TCRs, naturally selected in vivo for optimal affinity and specificity. T-knife is developing a pipeline of potential first/best-in-class TCR therapeutics against targets with …

Turbine was founded to overcome the limitations of existing methods in identifying oncology treatments that truly benefit the patients who receive them by combining molecular biology and artificial intelligence. The company has developed and validated the Simulated Cell, a proprietary and cutting-edge platform that runs billions of simulations prior to ever initiating preclinical development guiding …

Omniscope has developed an AI-enabled platform to perform high-precision immune profiling, which is the process of understanding why people respond differently to viruses, to inform research, diagnostics, and therapeutic development. The company’s OS-T technology allows mapping of a complete T cell response, up to 1 million T cells per clinical sample. Its other offering, OS-IP, …

Qubit Pharmaceuticals aims to speed up the lengthy and costly drug discovery process, where potential drugs are screened from a very large number of molecules. It increases the accuracy of these calculations by leveraging the power of its own 200 GPU supercomputer, called Gaia, developed in partnership with Nvidia. Qubit’s software, called Atlas, has been …

The company is developing a targeted radiopharmaceutical cancer treatment called Oncocidia. This innovative treatment involves extending the already successful use of Iodine-131 in treating thyroid cancer to treat solid cancers (primary and metastatic) elsewhere in the body. Iodine-131 is used to label the necrosis avid agent hypericin. Hypericin targets necrosis in a tumor and carries …

TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules, including cytokines that can stimulate or suppress T cells. The company’s patented TILT technology, which can be delivered locally and systemically, modifies the tumor microenvironment and eliminates its ability to suppress immune responses to cancer, thereby …

Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. The company is building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each …

Kaiku Health has developed a digital health intervention platform classified as a Medical Device in cancer care. Its algorithms screen symptoms, notify care teams and provide personalized support for patients. Kaiku Health has modules for over 25 cancer types across different cancer care pathways, enabling cancer clinics to provide optimized care through timely symptom management …

Perci Health has developed a platform that supports people living with cancer and also goes beyond cancer through personalized programmes. Said programmes include support across the whole cancer continuum, from preparing for treatment to support during treatment, recovery and rehabilitation and return to work. To that end, Perci offers tailored answers and access to high-quality …

With its AI-driven drug discovery platform, Tailor Bio is bringing precision medicine to the deadliest cancers. It provides clinical decision support to physicians, allowing them to select the best therapy for their patients’ treatments. To do this, Tailor Bio’s technology decodes chromosomal instability — a genomic phenomenon present in 80% of all cancers — and …

MVision AI provides is a cloud-based software service provider for radiotherapy treatment planning. Its AI-powered automatic segmentation tool helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. MVision’s deep learning model produces consistent contouring in minutes while maintaining the highest standards of quality for every patient, every time. As of …

Kuano combines quantum physics, AI and medicinal chemistry in an approach to transforming the discovery of therapeutics focused on enzyme inhibition. Enzymes represent the largest class of drug targets, with over $40 billion of pharmaceutical sales attributable to small molecule inhibitors of enzymes. The market is seeing considerable demand for enzyme inhibitors, which can provide …

A spin-out from Newcastle University, AMLo Biosciences is developing predictive tests for cancers with unmet needs. Its first product is an immunohistochemical test for non-ulcerated, cutaneous melanomas, which can accurately identify those tumors at low risk of recurrence/spread, reducing patient anxiety associated with cancer.

Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancers that are difficult to treat. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumors. The company is building a pipeline of next-generation DDR programs, including through …

A spin-out from The University of Copenhagen and Rigshospitalet, Adcendo is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (ADCs). The company’s drugs are directed at a target receptor uPARAP, which allows targeted therapy in several cancer forms where expression of the target has been found to be highly unregulated, including …

MyPL has developed a personalized augmented medicine platform built on a global approach to patient data, which helps healthcare professionals to determine the personalized therapeutic strategies accurately to be implemented for a given patient, particularly in the case of cancer patients. This unique data visualization solution allows a large amount of data as well as …

Kheiron Medical is on a mission to help breast cancer patients live longer, better lives through earlier detection. Its solution, called Mia (Mammography Intelligent Assessment), combines new deep learning methods, data science, and radiology insights to help doctors find malignancies in mammograms. Whilst many AI technologies are not designed to be inclusive, Kheiron’s technology has …

MindPeak builds automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Its tools assist cancer experts in providing reliable and reproducible diagnoses. This frees specialists from tedious, repetitive tasks such as the quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable. The company …

Elypta is a molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome, which are system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer non-invasively. Elypta is advancing a broad clinical program across different cancers, with …

Terapet has developed an add-on device to improve existing proton therapy, which is an advanced form of radiotherapy for cancer treatment that can target tumors with extreme precision. It is a non-invasive medical device placed close to the patient during the treatment to enable doctors to monitor the delivered proton dose inside the patients during …

Sarcura is developing an instrument platform for the GMP manufacturing of autologous cell therapies. Its platform combines microfluidic processing with silicon chip technology to enable real-time process control and manipulation on a cellular level supporting a fully automated manufacturing system. The company’s target is to scale global manufacturing capacity for patient-specific cell therapy cancer treatments …

CancerAppy has developed a platform based on Big Data and AI, specialized in the field of cancer research, developed by and for scientists and drug developers that fills the gap between basic data tools and pharma intelligence tools. Said platform is meant to efficiently and effectively de-risk the process of cancer drug discovery and development …

Founded in 2018, Vinehealth has built an app applying behavioral science and AI to deliver highly personalized support for cancer patients at scale. The platform also acts as a channel through which patients can be remotely monitored by their clinicians as they provide feedback on symptoms and report any treatment side effects. On the other …